Cardioprotection: Where to from here?

Cardiovascular Drugs and Therapy

Volumn 31, Issue 1, 2017, Pages 53-61

  Kloner, Robert A ^a,b   Hale, Sharon L ^a   Dai, Wangde ^a,b   Shi, Jianru ^a,b  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute myocardial infarction; Adenosine; Beta blockade; Hypothermia; Myocardial infarct size reduction; ST elevation myocardial infarction

Indexed keywords

ADENOSINE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOXIQUINE; DIOSGENIN; EXENDIN 4; GYY 4137; HYDROGEN SULFIDE; METFORMIN; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL (TOPIC); EXPERIMENTAL STUDY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INDUCED HYPOTHERMIA; INDUCED HYPOXEMIA; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PHYSICAL MEDICINE; PRIORITY JOURNAL; ADVERSE EFFECTS; ANIMAL; CARDIAC MUSCLE; DISEASE MODEL; HEART INFARCTION PREVENTION; HEART MUSCLE REPERFUSION; MORTALITY; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOTHERMIA, INDUCED; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84990854037     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6691-0     Document Type: Article

References (81)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics: 2015 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.
2. Boden H, Ahmed TA, Velders MA, et al. Peak and fixed-time high-sensitive troponin for prediction of infarct size, impaired left ventricular function, and adverse outcomes in patients with first ST-segment elevation myocardial infarction receiving percutaneous coronary intervention. Am J Cardiol. 2013;111(10):1387–93.
3. Turer AT, Mahaffey KW, Gallup D, et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med. 2005;6:12.
4. Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369(10):901–9.
5. Schwartz Longacre L, Kloner RA, Arai AE, et al. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute workshop. Circulation. 2011;124(10):1172–9.
6. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381(9861):166–75.
7. Hausenloy DJ, Bøtker HE, Condorelli G, et al. Translating cardioprotection for patient benefit: position paper from the working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013;98(1):7–27.
8. Lecour S, Bøtker HE, Condorelli G, et al. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014;104(3):399–411.
9. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65(14):1454–71.
10. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2016;pii:ehw224.
11. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–35.
12. Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012;59(11):969–78.
13. Roubille F, Mewton N, Elbaz M, et al. No post-conditioning in the human heart with thrombolysis in myocardial infarction flow 2-3 on admission. Eur Heart J. 2014;35(25):1675–82.
14. Freixa X, Bellera N, Ortiz-Pérez JT, et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J. 2012;33(1):103–12.
15. Hahn JY, Song YB, Kim EK, et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation. 2013;128(17):1889–96.
16. Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373(11):1021–31.
17. Ottani F, Latini R, Staszewsky L, et al. Cyclosporine a in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 2016;67(4):365–74.
18. Kumbhani, DH. The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: Ischemic Postconditioning During Primary PCI - DANAMI 3-iPOST - See: http://www.acc.org/latest-in-cardiology/clinical-trials/2016/03/29/22/46/danami-3-ipost#sthash.Sxq729qQ.dpuf.9.
19. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296–303.
20. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66(4):1142–74.
21. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34(6):1711–20.
22. Ross AM, Gibbons RJ, Stone GW, Kloner RA. Alexander RW; AMISTAD-II investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45(11):1775–80.
23. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27(20):2400–5.
24. Garcia-Dorado D, García-del-Blanco B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014;177(3):935–41.
25. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867–77.
26. Tian F, Chen YD, Lü SZ, et al. Intracoronary adenosine improves myocardial perfusion in late reperfused myocardial infarction. Chin Med J. 2008;121:195–9.
27. De Luca G, Iorio S, Venegoni L, Marino P. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS trial). Am J Cardiol. 2012;109:202–7.
28. Bulluck H, Sirker A, Loke YK, Garcia-Dorado D, Hausenloy DJ. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int J Cardiol. 2016;202:228–37.
29. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893–9.
30. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation. 1996;94:2193–200.
31. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation. 1997;96(5):1641–6.
32. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375(9716):727–34.
33. Sloth AD, Schmidt MR, Munk K, et al. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J. 2014;35(3):168–75.
34. Yellon DM, Ackbarkhan AK, Balgobin V, et al. Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis. J Am Coll Cardiol. 2015;65(25):2764–5.
35. Prunier F, Angoulvant D, Saint Etienne C, et al. The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res Cardiol. 2014;109(2):400.
36. Crimi G, Pica S, Raineri C, et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. JACC Cardiovasc Interv. 2013;6(10):1055–63.
37. Sharma V, Marsh R, Cunniffe B, Cardinale M, Yellon DM, Davidson SM. From protecting the heart to improving athletic performance - the benefits of local and remote ischaemic preconditioning. Cardiovasc Drugs Ther. 2015;29:573–88.
38. Yamanaka T, Kawai Y, Miyoshi T, et al. Remote ischemic preconditioning reduces contrast-induced acute kidney injury in patients with ST-elevation myocardial infarction: a randomized controlled trial. Int J Cardiol. 2015;178:136–41.
39. Zuo B, Wang F, Song Z, Xu M, Wang G. Using remote ischemic conditioning to reduce acute kidney injury in patients undergoing percutaneous coronary intervention: a meta-analysis. Curr Med Res Opin. 2015;31(9):1677–85.
40. Yetgin T, Manintveld OC, Boersma E, et al. Remote ischemic conditioning in percutaneous coronary intervention and coronary artery bypass grafting. Circ J. 2012;76(10):2392–404.
41. Le Page S, Bejan-Angoulvant T, Angoulvant D, Prunier F. Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Basic Res Cardiol. 2015;110(2):11.
42. Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med. 2015;373:1408–17.
43. Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med. 2015;373:1397–407.
44. Hale SL, Kloner RA. Ischemic preconditioning and myocardial hypothermia in rabbits with prolonged coronary artery occlusion. Am J Phys. 1999;276(6 Pt 2):H2029–34.
45. Gho BC, van den Doel MA, Duncker DJ, Schoemaker RG, Verdouw PD. Myocardial infarct size limiting effect of low body temperature in rats depends on the duration of coronary artery occlusion. Circulation. 1997;96:1064.
46. Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther. 2015;20(2):193–202.
47. Götberg M, Olivecrona GK, Koul S, et al. A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv. 2010;3(5):400–7.
48. Erlinge D, Götberg M, Lang I, et al. Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol. 2014;63(18):1857–65.
49. Erlinge D, Götberg M, Noc M, et al. Therapeutic hypothermia for the treatment of acute myocardial infarction-combined analysis of the RAPID MI-ICE and the CHILL-MI trials. Ther Hypothermia Temp Manag. 2015;5(2):77–84.
50. Nichol G, Strickland W, Shavelle D, et al. Prospective, multicenter, randomized, controlled pilot trial of peritoneal hypothermia in patients with ST-segment- elevation myocardial infarction. Circ Cardiovasc Interv. 2015;8(3):e001965.
51. Maroko PR, Kjekshus JK, Sobel B, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43:67–82.
52. Rasmussen MM, Reimer KA, Kloner RA, et al. Infarct size reduction by propranolol before and after coronary ligation in dogs. Circulation. 1977;56:794–8.
53. Kloner RA, Fishbein MC, Braunwald E, et al. Effect of propranolol on mitochondrial morphology during acute myocardial ischemia. Am J Cardiol. 1978;41:880–6.
54. Ibanez B, Macaya C, Sánchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation. 2013;128(14):1495–503.
55. García-Ruiz JM, Fernández-Jiménez R, García-Alvarez A, et al. Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function. J Am Coll Cardiol. 2016;67(18):2093–104.
56. Kloner RA, Braunwald E. Intravenous Beta-blockade for limiting myocardial infarct size: rejuvenation of a concept. J Am Coll Cardiol. 2016;67(18):2105–7.
57. Roolvink V, Ibanez J, Ottervanger J-P, et al. Early intravenous beta-blocker in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol. 2016;67:2705–15.
58. Newby LK. Intravenous beta-blockers for cardioprotection in STEMI. The Saga Continues J Am Coll Cardiol. 2016;67:2716–8.
59. Stone GW, Martin JL, de Boer MJ, et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv. 2009;2(5):366–75.
60. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370(9597):1483–93.
61. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491–9.
62. Lønborg J, Kelbæk H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5(2):288–95.
63. Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ Res. 2013;113(4):451–63.
64. Hausenloy DJ, Botker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 2016;pii:ehw 145.
65. Kleinbongard P, Heusch G. Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection? Br J Pharmacol. 2015;172:2010–25.
66. Jones SP, Tang XL, Guo Y, et al. The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res. 2015;116:572–86.
67. Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015;78:23–34.
68. Pell VR, Chouchani ET, Murphy MP, Brookes PS, Krieg T. Moving forwards by blocking back-flow: the Yin and Yang of MI therapy. Circ Res. 2016;118(5):898–906.
69. Shen Z, Ye C, McCain K, Greenberg ML. The role of cardiolipin in cardiovascular health. Biomed Res Int. 2015;2015:891707.
70. Zhang J, Nadtochiy SM, Urciuoli WR, Brookes PS. The cardioprotective compound cloxyquin uncouples mitochondria and induces autophagy. Am J Physiol Heart Circ Physiol. 2016;310(1):H29–38.
71. Badalzadeh R, Yousefi B, Tajaddini A, Ahmadian N. Diosgenin-induced protection against myocardial ischaemia-reperfusion injury is mediated by mitochondrial KATP channels in a rat model. Perfusion. 2015;30(7):565–71.
72. Meng G, Wang J, Xiao Y, et al. GYY4137 protects against myocardial ischemia and reperfusion injury by attenuating oxidative stress and apoptosis in rats. J Biol Res. 2015;29(3):203–13.
73. Zhao Y, Yang C, Organ C, et al. Design, synthesis, and cardioprotective effects of N-mercapto-based hydrogen sulfide donors. J Med Chem. 2015;58(18):7501–11.
74. Stratmann B, Tschoepe D. Heart in diabetes: not only a macrovascular disease. Diabetes Care. 2011;34(Suppl 2):S138–44.
75. Bhamra GS, Hausenloy DJ, Davidson SM. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol. 2008;103:274–84.
76. Oidor-Chan VH, Hong E, Pérez-Severiano F, et al. Fenofibrate plus metformin produces cardioprotection in a type 2 diabetes and acute myocardial infarction model. PPAR Res. 2016;2016:8237264.
77. Lexis CP, van der Horst IC, Lipsic E. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA. 2014;311:1526–35.
78. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol. 2004;44(2):276–86.
79. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol. 2008;103(6):501–13.
80. Cohen MV, Downey JM. Status of P2Y12 treatment must be considered in evaluation of myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2015;106(1):8.
81. Kloner RA, Schwartz LL. State of the science of cardioprotection: challenges and opportunities: proceedings of the 2010 NHLBI workshop on cardioprotection. J Cardiovasc Pharmacol Ther. 2011;16(3–4):223–32.